Stoke Therapeutics, Inc. STOK
Set alert
At close
Pre-market · Nov 2, 4:11 AM ET
- YTD
- -17.17%
- 1 year
- -12.48%
- Open
- 26.04
- Prev close
- 26.35
- Mkt cap
- 1.70B
- Vol
- 1.86M
- Avg vol
- 1.05M
- EPS
- -3.81
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 25.86
- High
- 26.72
- Forward P/E
- -7.45
- Beta
- 1.26
- Short ratio
- 10.28
- Inst. own
- 125.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 15, 2027
- 50-d avg
- 27.53
- 200-d avg
- 30.94
- 1y target
- 46.46
6M chart
Events in this range
- May 7, 2026Earnings: -0.79; estimate -0.8; surprise 1.25%
- May 11, 2026Rating: BTIG · Buy → Buy
- Jul 13, 2026Rating: Goldman Sachs · — → Buy
- Aug 3, 2026Earnings: -0.93; estimate -0.795; surprise -16.98%
- Aug 4, 2026Rating: Chardan Capital · Buy → Buy
- Aug 4, 2026Rating: Canaccord Genuity · Buy → Buy
- Aug 4, 2026Rating: Wedbush · Outperform → Outperform
- Aug 4, 2026Rating: Guggenheim · Buy → Buy
- Oct 29, 2026Earnings: -1.08; estimate -0.92914; surprise -16.24%
Signals (33)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 15, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 7, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 25, 2026 | 1 month ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| SMA: Bullish | Aug 21, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bearish | Aug 13, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 31, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 30, 2026 | 3 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 13, 2026 | 3 months ago |
| SMA: Bearish | Jul 10, 2026 | 3 months ago |
| SMA: Bullish | Jul 9, 2026 | 3 months ago |
| SMA: Bearish | Jul 8, 2026 | 3 months ago |
| SMA: Bullish | Jul 7, 2026 | 3 months ago |
| SMA: Bullish | Jun 26, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 12, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 8, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 4, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| MACD: Buy Signal | May 28, 2026 | 5 months ago |
| RSI: Oversold | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 7, 2026 | 5 months ago |
| SMA: Bullish | May 6, 2026 | 5 months ago |
| SMA: Bearish | May 5, 2026 | 6 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
Key statistics
- Market cap
- 1.70B
- Enterprise value
- 1.41B
- Trailing P/E
- 0.00
- Forward P/E
- -7.45
- PEG ratio
- 0.00
- Price / sales
- 61.49
- Price / book
- 4.39
- EPS (TTM)
- -3.81
- Beta
- 1.26
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 27.59M
- Revenue growth
- -32.50%
- Free cash flow
- -106.20M
- Total cash
- 292.82M
- Total debt
- 2.68M
- Return on equity
- -61.10%
- Shares outstanding
- 64.53M
- Short % of float
- 16.51%
- 50-day average
- 27.53
- 200-day average
- 30.94
Analyst view
Consensus: none
- Target (low)
- 35.00
- Target (mean)
- 46.46
- Target (high)
- 60.00
- Strong buy2
- Buy12
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 15, 2027
Expected Mar 15, 2027. Consensus EPS estimate -0.97033.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 15, 2027 | Mar 30, 2027 | -1.06 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | -0.92914 | -1.08 | -0.15 | -16.24% |
| Aug 3, 2026 | Jun 30, 2026 | -0.795 | -0.93 | -0.13 | -16.98% |
| May 7, 2026 | Mar 31, 2026 | -0.80 | -0.79 | +0.01 | +1.25% |
| Mar 16, 2026 | Dec 31, 2025 | -0.75 | -0.97 | -0.22 | -29.33% |
| Nov 4, 2025 | Sep 30, 2025 | -0.54 | -0.65 | -0.11 | -20.37% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 4, 2026 | Guggenheim | reit | Buy | Buy |
| Aug 4, 2026 | Wedbush | main | Outperform | Outperform |
| Aug 4, 2026 | Canaccord Genuity | main | Buy | Buy |
| Aug 4, 2026 | Chardan Capital | main | Buy | Buy |
| Jul 13, 2026 | Goldman Sachs | init | — | Buy |
| May 11, 2026 | BTIG | reit | Buy | Buy |
About Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- stoketherapeutics.com
News
- Stoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call Transcript
- Stoke Therapeutics Q3 Earnings Call Highlights
- Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
- Stoke Therapeutics Q3 2026 Earnings Call Transcript
- Stoke Therapeutics Q3 EPS $(1.08) Misses $(0.93) Estimate, Sales $11.255M Beat $8.185M Estimate
- Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates
- Stoke Therapeutics Presents Data For STK-002 Supporting Disease-Modifying Potential In Autosomal Dominant Optic Atrophy At AAO 2026 Annual Meeting
Your note
Sign in to keep a note on STOK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLAN JONATHAN | General Counsel | Sale | Aug 17, 2026 | 21,225 |
| HOITT JASON | Officer | Sale | Mar 17, 2026 | 10,276 |
| KAYE EDWARD M | Director | Sale | Aug 17, 2026 | 124,557 |
| KRAINER ADRIAN R | Director | Sale | Mar 9, 2026 | 283,302 |
| LEGGETT THOMAS | Chief Financial Officer | Sale | Mar 17, 2026 | 10,172 |
| LEVIN ARTHUR A. | Director | Sale | Mar 12, 2026 | 22,216 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.11% | 5,877,357 | 154.52M | Jun 29, 2026 |
| RTW Investments LP | 8.72% | 5,623,525 | 147.84M | Jun 29, 2026 |
| FMR, LLC | 8.23% | 5,313,100 | 139.68M | Jun 29, 2026 |
| Lynx1 Capital Management Lp | 6.26% | 4,038,404 | 106.17M | Jun 29, 2026 |
| Redmile Group, LLC | 6.12% | 3,945,920 | 103.74M | Jun 29, 2026 |
| Wellington Management Group, LLP | 5.45% | 3,519,301 | 92.52M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 3.50% | 2,260,550 | 59.43M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.92% | 1,884,647 | 49.55M | Jun 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 2.30% | 1,482,681 | 38.98M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.21% | 1,426,549 | 37.50M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.03% | 1,311,567 | 34.48M | Sep 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1.13% | 729,201 | 19.17M | Jun 29, 2026 |